featured
Safety and Efficacy of Deucravacitinib Over 3 Years in Patients With Moderate to Severe Plaque Psoriasis
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
JAMA Dermatology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Safety and Efficacy of Deucravacitinib in Moderate to Severe Plaque Psoriasis For Up to 3 Years: An Open-Label Extension of Randomized Clinical Trials
JAMA Dermatol 2024 Nov 27;[EPub Ahead of Print], AW Armstrong, M Lebwohl, RB Warren, H Sofen, S Imafuku, M Ohtsuki, L Spelman, T Passeron, KA Papp, RM Kisa, J Vaile, V Berger, E Vritzali, K Hoyt, MJ Colombo, J Scotto, S Banerjee, B Strober, D Thaçi, A BlauveltFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.